

#10



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Salfeld, J.G. et al.

Serial No.: 08/599,226

Filed: February 9, 1996

For: *Human Antibodies that Bind Human TNF α*

Attorney Docket No.: BBI-043

Group Art Unit: 1816

Examiner: E. Eisenschenk

Assistant Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

2-5-98

Date of Signature and of Mail Deposit

By:

Catherine J. Kara

Catherine J. Kara, Ph.D.

Reg. No. 41,106

Agent for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicant and their agent are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Enclosed is a check for \$240.00 pursuant to 1.17(p). No additional costs are believed to be due in connection with the filing of this disclosure. If additional costs are due, please charge the appropriate fee as required under 37 CFR 1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Catherine J. Kara
Registration No. 41,106
Agent for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400
Date: February 5, 1998